Core Viewpoint - Iradimed Corporation will release its 2025 second quarter financial results on August 1, 2025, and will host a conference call to discuss these results [1][2]. Company Overview - Iradimed Corporation is a leader in developing MRI-compatible medical devices, specifically known for its non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3]. - The company has developed the patented MRidium® MRI compatible IV infusion pump system, which eliminates dangers associated with standard infusion pumps that contain magnetic components [3]. - The Iradimed 3880 MRI compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to operate in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4]. Product Features - The MRidium® system provides accurate and safe delivery of anesthesia and IV fluids during MRI scans, crucial for critically ill patients and children who require sedation [3]. - The Iradimed 3880 system features wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2 monitoring, and advanced multi-gas anesthetic agent unit capabilities [4].

Core Insights - Iradimed Corporation has received FDA 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System, reinforcing its position as the only supplier of non-magnetic MRI infusion pump devices [1][3] - The MRidium® 3870 is designed to meet the increasing demand for safe fluid delivery in MRI environments, featuring advanced technology such as a non-magnetic ultrasonic pump motor and an intuitive touchscreen interface [2][3] Company Overview - Iradimed Corporation specializes in developing innovative MRI-compatible medical devices, including infusion pumps and patient monitoring systems [4][5] - The company is recognized as the only provider of a non-magnetic intravenous infusion pump system specifically designed for MRI procedures, addressing safety concerns associated with standard infusion pumps [5] Product Features - The MRidium® 3870 includes features such as non-interfering RF emissions, non-ferrous components, and the ability to operate as a four-channel IV infusion pump system, enhancing patient safety and workflow efficiency [2][3] - The system also incorporates a modern drug library solution, accommodating various patient care areas and drug listings, which broadens its application in MRI settings [2] Strategic Plans - The company plans to strategically roll out the MRidium® 3870 infusion pump, with initial deployments to select healthcare facilities in Q4 2025, followed by a ramp-up in material shipments throughout 2026 [3]

[Cautionary Note Regarding Forward-Looking Statements](index=3&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) This report contains forward-looking statements, subject to numerous risks and uncertainties that could cause actual results to differ materially - This report contains forward-looking statements, subject to **numerous risks and uncertainties** that could cause actual results to differ materially[8](index=8&type=chunk) - Key risks include **FDA 510(k) clearance**, **reliance on limited products**, **supply chain integrity**, **competition**, **regulatory changes**, and **geopolitical impacts**[8](index=8&type=chunk)[10](index=10&type=chunk)[13](index=13&type=chunk) - The company disclaims any obligation to update forward-looking statements, advising readers to consider **detailed risks** in this 10-Q and 2024 Annual Report on Form 10-K[11](index=11&type=chunk) [Part I: Financial Information](index=8&type=section&id=Part%20I%20Financial%20Information) [Item 1: Financial Statements](index=8&type=section&id=Item%201%20Financial%20Statements) Unaudited Q1 2025 financials reflect asset growth, 11% revenue increase, and strong net income, with robust operating cash flow [Condensed Balance Sheets](index=8&type=section&id=Condensed%20Balance%20Sheets) Total assets increased by March 31, 2025, primarily due to property and equipment investments, with stockholders' equity also growing Condensed Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $50,331 | $52,234 | | Total current assets | $75,137 | $75,242 | | Property and equipment, net | $20,378 | $16,811 | | Total assets | $101,729 | $98,326 | | **Liabilities & Equity** | | | | Total current liabilities | $8,473 | $8,512 | | Total liabilities | $11,675 | $11,507 | | Total stockholders' equity | $90,054 | $86,819 | | Total liabilities and stockholders' equity | $101,729 | $98,326 | [Condensed Statements of Operations](index=9&type=section&id=Condensed%20Statements%20of%20Operations) Q1 2025 saw an 11% revenue increase, with gross profit rising and net income growing 13.3%, leading to higher diluted EPS Q1 2025 vs Q1 2024 Statement of Operations (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | $19,511 | $17,598 | 10.9% | | Gross Profit | $14,843 | $13,388 | 10.9% | | Income from Operations | $5,431 | $4,748 | 14.4% | | Net Income | $4,687 | $4,137 | 13.3% | | Diluted EPS | $0.37 | $0.32 | 15.6% | [Condensed Statements of Stockholders' Equity](index=10&type=section&id=Condensed%20Statements%20of%20Stockholders%27%20Equity) Stockholders' equity increased in Q1 2025, primarily driven by net income and partially offset by declared dividends - Key changes in stockholders' equity for Q1 2025 include **net income of $4.7 million**, **dividends declared of $2.2 million**, and **stock-based compensation expense of $0.8 million**[20](index=20&type=chunk) [Condensed Statements of Cash Flows](index=11&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Q1 2025 cash flows show strong operating cash, significant investment in property, and cash used for financing, resulting in a net decrease Q1 2025 vs Q1 2024 Cash Flow Summary (in thousands) | Cash Flow Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $4,292 | $3,883 | | Net cash used in investing activities | ($3,917) | ($479) | | Net cash used in financing activities | ($2,278) | ($8,040) | | **Net decrease in cash** | **($1,903)** | **($4,636)** | - The significant increase in cash used for investing activities in Q1 2025 is attributed to **$3.7 million in purchases of property and equipment**, compared to just **$0.3 million in Q1 2024**[23](index=23&type=chunk) - Cash used in financing activities decreased significantly year-over-year, as Q1 2024 included a **large special dividend payment of nearly $8.0 million**, compared to the **regular quarterly dividend of $2.2 million in Q1 2025**[23](index=23&type=chunk) [Notes to Unaudited Condensed Financial Statements](index=12&type=section&id=Notes%20to%20Unaudited%20Condensed%20Financial%20Statements) Notes confirm single segment, detail U.S. revenue growth, international decline, ongoing IRS examination, and a declared quarterly dividend Revenue Breakdown by Geography and Type (Q1 2025 vs Q1 2024, in thousands) | Revenue Category | Q1 2025 | Q1 2024 | Change (%) | | :--- | :--- | :--- | :--- | | **By Geography** | | | | | United States | $15,953 | $13,409 | 19.0% | | International | $3,558 | $4,189 | (15.1%) | | **By Type** | | | | | Total Devices | $12,962 | $11,904 | 8.9% | | Disposables | $4,947 | $4,014 | 23.2% | - The company is currently under an **IRS examination** for the tax year ended December 31, 2021, but has not accounted for any proposed adjustments[49](index=49&type=chunk) - On May 5, 2025, the Board of Directors declared a **regular quarterly cash dividend of $0.17 per share**, payable on May 30, 2025[58](index=58&type=chunk) [Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes Q1 2025 revenue growth to strong U.S. demand, maintaining stable gross margins despite rising operating expenses, and anticipates continued fiscal 2025 growth - The company is a leader in **MRI compatible medical devices**, including its **non-magnetic MRidium® IV infusion pump system**, the **3880 patient vital signs monitoring system**, and the **3600 ferromagnetic detection device**[61](index=61&type=chunk)[63](index=63&type=chunk)[64](index=64&type=chunk) - For the remainder of fiscal year 2025, the company anticipates **higher revenue** compared to 2024, driven by increased sales across its product lines, and expects **higher operating expenses** in sales, marketing, regulatory, and G&A areas[69](index=69&type=chunk) [Results of Operations](index=26&type=section&id=Results%20of%20Operations) Q1 2025 revenue increased 11% driven by U.S. sales growth, offsetting international decline, with stable gross margins and varied operating expense changes Revenue by Type (Q1 2025 vs Q1 2024, in millions) | Revenue Type | Q1 2025 | Q1 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Total Devices | $13.0 | $11.9 | 9% | | Disposables | $4.9 | $4.0 | 23% | | Services and other | $1.0 | $1.2 | (13%) | | **Total Revenue** | **$19.5** | **$17.6** | **11%** | - General and administrative expenses increased by **15% to $4.6 million**, primarily due to higher legal, professional, and payroll expenses[84](index=84&type=chunk) - Research and development expenses decreased by **25% to $0.6 million**, mainly due to a reduction in the purchase of prototype materials[86](index=86&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains strong liquidity with substantial cash and working capital, with operating cash flow supporting investments and dividends, and a shelf registration available - The company has a **shelf registration statement on Form S-3**, effective May 8, 2024, allowing for the sale of up to **$75.0 million of its common stock**, with the full amount remaining available as of March 31, 2025[93](index=93&type=chunk) - Cash used in investing activities increased to **$3.9 million in Q1 2025** from **$0.5 million in Q1 2024**, primarily due to **construction costs for a new facility**[96](index=96&type=chunk) - The company commenced a **regular quarterly dividend in 2024**, in addition to a **special dividend paid in March 2024**[97](index=97&type=chunk) [Item 3: Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=Item%203%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes in market risks have occurred since the 2024 Annual Report on Form 10-K - There have been **no material changes in market risks** since the 2024 Annual Report[103](index=103&type=chunk) [Item 4: Controls and Procedures](index=32&type=section&id=Item%204%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal control over financial reporting - The Chief Executive Officer and Chief Financial Officer concluded that the company's **disclosure controls and procedures were effective** as of March 31, 2025[105](index=105&type=chunk) - **No changes to internal control over financial reporting** occurred during the quarter that would have a material effect[106](index=106&type=chunk) [Part II: Other Information](index=33&type=section&id=Part%20II%20Other%20Information) [Item 1: Legal Proceedings](index=33&type=section&id=Item%201%20Legal%20Proceedings) The company is not currently party to any legal proceedings expected to have a material adverse effect on its operations - The company may become party to legal proceedings in the ordinary course of business but does not believe any known matters will have a **material adverse effect**[108](index=108&type=chunk) [Item 1A: Risk Factors](index=33&type=section&id=Item%201A%20Risk%20Factors) No material changes to risk factors from the 2024 Annual Report, except for expanded discussion on potential adverse effects of changing trade policies and tariffs - A key risk factor highlighted is the **uncertainty and potential adverse impact of changes in trade policies**, such as tariffs imposed by the U.S. and retaliatory measures by other countries[110](index=110&type=chunk) - Tariffs could **increase the cost of sourced materials**, impact product pricing, and potentially **reduce sales and profitability**, making the company susceptible to trade disputes due to global sales and sourcing[111](index=111&type=chunk) [Item 2: Unregistered Sale of Equity Securities and Use of Proceeds](index=34&type=section&id=Item%202%20Unregistered%20Sale%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities occurred during the period - None[113](index=113&type=chunk) [Item 3: Default Upon Senior Securities](index=35&type=section&id=Item%203%20Default%20Upon%20Senior%20Securities) Not applicable - Not Applicable[114](index=114&type=chunk) [Item 4: Mine Safety Disclosures](index=35&type=section&id=Item%204%20Mine%20Safety%20Disclosures) Not applicable - Not Applicable[115](index=115&type=chunk) [Item 5: Other Information](index=35&type=section&id=Item%205%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 trading arrangements during Q1 2025 - No directors or officers adopted or terminated a **Rule 10b5-1 trading arrangement** during the quarter ended March 31, 2025[116](index=116&type=chunk) [Item 6: Exhibits](index=36&type=section&id=Item%206%20Exhibits) The report lists various exhibits filed with the Form 10-Q, including CEO and CFO certifications and XBRL data files - Key exhibits include **CEO and CFO certifications** (31.1, 31.2, 32.1) and **Inline XBRL documents** (101 series)[117](index=117&type=chunk)

Financial Data and Key Metrics Changes - For Q1 2025, the company achieved revenue of $19.5 million, an 11% increase from $17.6 million in Q1 2024 [4][13] - Gross profit margin was reported at 76.1%, consistent with Q1 2024 [14] - GAAP diluted earnings per share increased by 16% to $0.37 from $0.32 in Q1 2024 [15] - Non-GAAP adjusted net income was $5.3 million or $0.42 per diluted share, up 17% from $4.6 million or $0.36 per diluted share in Q1 2024 [16] Business Line Data and Key Metrics Changes - Revenue from IV infusion pump systems grew 16% to $6 million, while disposable revenue increased 23% to $4.9 million [13][14] - Patient vital signs monitoring systems revenue remained steady at $6.5 million [14] - Service revenue remained stable at $1 million [14] Market Data and Key Metrics Changes - Domestic sales accounted for 82% of total revenue in Q1 2025, up from 76% in Q1 2024 [13] - Domestic revenue increased 19% to $16 million, while international sales declined 15% to $3.5 million [14] Company Strategy and Development Direction - The company is focused on increasing monitoring sales in 2025, anticipating a decline in pump revenues later in the year [22] - The new 3,870 MRIV pump is expected to contribute to revenue in 2026, with clearance anticipated in mid-2025 [10] - The company is nearing completion of a new facility, with full operations expected by July 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the impact of tariffs, noting that only 3% of revenue is linked to high-tariff sources [6][8] - The FDA's responsiveness has been positive, with ongoing interactions indicating progress towards device clearance [27] - The company expects Q2 2025 revenue guidance of $19.7 million to $19.9 million, with full-year revenue guidance of $78 million to $82 million [11][12] Other Important Information - Operating expenses increased to $9.4 million, primarily due to higher general and administrative costs [15] - Cash flow from operations was $4.3 million, up 10% from Q1 2024 [16] Q&A Session Summary Question: Inquiry about disposables performance - Management indicated that the strong disposable revenue was partly due to working down backlog and expects growth to align with capital growth [18][19] Question: Composition of bookings and monitoring sales recovery - Management confirmed strong bookings for monitoring systems in Q1 and early Q2, indicating confidence in recovery [21][24] Question: Status of FDA interactions and clearance timeline - Management provided updates on FDA interactions, indicating ongoing communication and a hopeful timeline for clearance within a few weeks [25][27]

Core Viewpoint - iRadimed (IRMD) reported quarterly earnings of $0.42 per share, slightly missing the Zacks Consensus Estimate of $0.43 per share, but showing an increase from $0.36 per share a year ago [1][2] Financial Performance - The company posted revenues of $19.51 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.26%, compared to $17.6 million in the same quarter last year [2] - Over the last four quarters, iRadimed has exceeded consensus revenue estimates four times [2] Stock Performance - iRadimed shares have declined approximately 2.8% since the beginning of the year, while the S&P 500 has seen a decline of 3.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.45 on revenues of $20.31 million, and for the current fiscal year, it is $1.79 on revenues of $80.81 million [7] - The trend of estimate revisions for iRadimed is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Instruments industry, to which iRadimed belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Data and Key Metrics Changes - For Q1 2025, the company achieved revenue of $19.5 million, an 11% increase from $17.6 million in Q1 2024 [4][11] - Gross profit margin was reported at 76.1%, consistent with Q1 2024 [12] - GAAP diluted earnings per share increased by 16% to $0.37 from $0.32 in Q1 2024 [13] - Non-GAAP adjusted net income was $5.3 million or $0.42 per diluted share, up 17% from $4.6 million or $0.36 per diluted share in Q1 2024 [14] Business Line Data and Key Metrics Changes - Revenue from IV infusion pump systems grew 16% to $6 million, while disposable revenue increased 23% to $4.9 million [11][12] - Patient vital signs monitoring systems revenue remained steady at $6.5 million [12] - Domestic sales accounted for 82% of total revenue, up from 76% in Q1 2024, with domestic revenue increasing 19% to $16 million [12] Market Data and Key Metrics Changes - International sales declined 15% to $3.5 million [12] - Device revenue increased 9% to $13 million, driven by pump revenue and FMD systems [12] Company Strategy and Development Direction - The company is focused on increasing monitoring sales in 2025, anticipating a decline in pump revenues later in the year [21] - The new 3,870 MRIV pump is expected to be a revenue driver in 2026, with clearance anticipated in mid-2025 [9][10] - The company is nearing completion of a new facility, with full operations expected by July 2025 [10] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the impact of tariffs, noting that only 3% of revenue is connected to high tariff sources [6][7] - The FDA's responsiveness has been positive, with ongoing interactions indicating progress towards device clearance [25][27] - The company expects Q2 2025 revenue guidance of $19.7 million to $19.9 million, reiterating full-year revenue guidance of $78 million to $82 million [10] Other Important Information - Operating expenses were $9.4 million, or 48% of revenue, down from 49% in Q1 2024 [12] - Cash flow from operations was $4.3 million, up 10% from $3.9 million in Q1 2024 [14] Q&A Session Summary Question: Any anomalies in disposable revenue growth? - Management indicated that some backlog was worked down in Q1, contributing to the growth, but expects future growth to align with capital growth [17][18] Question: Confidence in monitoring sales recovery? - Management emphasized efforts to boost monitoring sales through adjusted compensation structures, with strong bookings already seen in Q2 [20][22] Question: Status of FDA interactions and clearance timeline? - Management noted ongoing interactive questions from the FDA, suggesting a positive sign, with expectations for clarity in the next three to four weeks [24][27]

[Financial Performance and Outlook](index=1&type=section&id=Financial%20Performance%20and%20Outlook) This section details IRADIMED's Q1 2025 financial performance, management commentary, guidance, and comprehensive financial analysis [Q1 2025 Financial Highlights](index=1&type=section&id=Q1%202025%20Financial%20Highlights) IRADIMED reported its fifteenth consecutive quarter of record revenue, reaching $19.5 million in Q1 2025, an 11% year-over-year increase, with GAAP diluted EPS growing 16% to $0.37 and non-GAAP diluted EPS rising 17% to $0.42 Q1 2025 Key Financial Metrics (YoY) | Metric | Q1 2025 (USD) | Q1 2024 (USD) | Change | | :--- | :--- | :--- | :--- | | Revenue | $19.5M | $17.6M | +11% | | Net Income | $4.7M | $4.1M | +15% | | GAAP Diluted EPS | $0.37 | $0.32 | +16% | | Non-GAAP Net Income | $5.3M | $4.6M | +15% | | Non-GAAP Diluted EPS | $0.42 | $0.36 | +17% | - The Board of Directors declared a regular quarterly cash dividend of **$0.17 per share**, payable on May 30, 2025[5](index=5&type=chunk)[7](index=7&type=chunk) [Management Commentary](index=1&type=section&id=Management%20Commentary) The CEO attributed the strong Q1 performance to sustained demand for the company's innovative products and operational excellence, with a new manufacturing facility on track for completion in July 2025 - The company achieved its **fifteenth consecutive quarter of record revenue**, highlighting sustained demand[3](index=3&type=chunk) - The new manufacturing facility is expected to be completed in **July 2025**, positioning the company to support planned growth[3](index=3&type=chunk)[10](index=10&type=chunk) [Financial Guidance](index=1&type=section&id=Financial%20Guidance) IRADIMED reaffirmed its full-year 2025 guidance and issued Q2 2025 guidance, projecting revenue and non-GAAP diluted EPS ranges for both periods Q2 2025 Financial Guidance | Metric | Guidance Range (USD) | | :--- | :--- | | Revenue | $19.7M - $19.9M | | GAAP Diluted EPS | $0.37 - $0.40 | | Non-GAAP Diluted EPS | $0.41 - $0.44 | Full Year 2025 Financial Guidance (Reaffirmed) | Metric | Guidance Range (USD) | | :--- | :--- | | Revenue | $78.0M - $82.0M | | GAAP Diluted EPS | $1.55 - $1.65 | | Non-GAAP Diluted EPS | $1.71 - $1.81 | - The non-GAAP guidance for the full year and second quarter of 2025 excludes estimated stock-based compensation expense, net of tax, of approximately **$2.6 million** and **$0.6 million**, respectively[12](index=12&type=chunk) [Detailed Financial Analysis](index=2&type=section&id=Detailed%20Financial%20Analysis) This section details the company's financial performance, highlighting revenue growth from devices and domestic sales, alongside profitability, cash flow, and balance sheet health [Revenue Analysis](index=2&type=section&id=Revenue%20Analysis) Total revenue for Q1 2025 increased 11% YoY to $19.5 million, driven by a 9% increase in device revenue, particularly MRI Compatible IV Infusion Pump Systems, with domestic sales accounting for 82% Revenue by Segment (Q1 2025 vs Q1 2024, in USD) | Segment | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | MRI Compatible IV Infusion Pump Systems | 5,999,212 | 5,192,680 | | MRI Compatible Patient Vital Signs Monitoring Systems | 6,544,679 | 6,461,658 | | Total Devices revenue | 12,962,095 | 11,904,038 | | Disposables | 4,947,088 | 4,013,875 | | Services and other | 1,041,255 | 1,193,075 | | **Total revenue** | **19,510,637** | **17,598,119** | - Domestic sales represented **82%** of total revenue for Q1 2025, compared to **76%** for the same period in 2024[9](index=9&type=chunk) [Profitability Analysis](index=2&type=section&id=Profitability%20Analysis) The company maintained a strong gross profit margin of 76.1%, with income from operations growing 14.4% to $5.4 million and net income increasing 13.3% to $4.7 million - The gross profit margin was constant at **76.1%** for the three months ended March 31, 2025 and 2024[9](index=9&type=chunk) Condensed Statement of Operations (Q1 2025 vs Q1 2024, in USD) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Gross Profit | 14,842,806 | 13,387,723 | | Income from Operations | 5,431,456 | 4,748,347 | | Net Income | 4,687,429 | 4,136,533 | [Cash Flow and Balance Sheet](index=2&type=section&id=Cash%20Flow%20and%20Balance%20Sheet) Cash flow from operations for Q1 2025 was $4.3 million, a 10% increase YoY, but free cash flow declined significantly to $0.4 million due to increased capital expenditures for a new facility, while the balance sheet remains strong - Cash flow from operations increased by **10%** to **$4.3 million** in Q1 2025[10](index=10&type=chunk) Free Cash Flow (Q1 2025 vs Q1 2024, in USD) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | 4,292,092 | 3,883,155 | | Less: Capital Expenditures | (3,917,300) | (478,804) | | **Free cash flow** | **374,792** | **3,404,351** | - The company anticipates spending an additional **$3.0 million** in cash on its new facility until its expected completion in **July 2025**[10](index=10&type=chunk) Key Balance Sheet Items (in USD) | Metric | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total Assets | 101,729,435 | 98,325,775 | | Total Liabilities | 11,675,005 | 11,507,019 | | Total Stockholders' Equity | 90,054,430 | 86,818,756 | [Non-GAAP Financial Measures](index=2&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) The company utilizes non-GAAP financial measures, such as non-GAAP net income and free cash flow, to offer investors additional perspectives on its operating performance, primarily by excluding stock-based compensation expenses - The company uses non-GAAP measures to provide supplemental perspectives on performance, primarily by excluding stock-based compensation expense, net of tax[13](index=13&type=chunk)[15](index=15&type=chunk) Reconciliation of GAAP to Non-GAAP Net Income (Q1 2025, in USD) | Metric | Amount | | :--- | :--- | | Net income (GAAP) | 4,687,429 | | Stock-based compensation expense, net of tax | 654,243 | | **Non-GAAP net income** | **5,341,672** | | Non-GAAP net income per share – diluted | $0.42 | - Free cash flow is calculated as net cash from operating activities less capital expenditures for internal software and property/equipment purchases[16](index=16&type=chunk) [Corporate Information](index=3&type=section&id=Corporate%20Information) This section details IRADIMED CORPORATION's MRI-compatible medical device business and Q1 2025 earnings conference call information [About IRADIMED CORPORATION](index=3&type=section&id=About%20IRADIMED%20CORPORATION) IRADIMED CORPORATION is a medical device company specializing in innovative MRI-compatible products, including the MRidium® IV infusion pump and Iradimed 3880 patient vital signs monitoring system, ensuring patient safety during MRI procedures - The company is the sole known provider of a non-magnetic IV infusion pump system (MRidium®) specifically designed for safe use during MRI procedures[23](index=23&type=chunk) - The Iradimed 3880 MRI-compatible patient vital signs monitoring system is designed to operate dependably in magnetic fields up to **30,000 gauss**, allowing it to be used almost anywhere in an MRI scanner room[24](index=24&type=chunk) - The company's products enable seamless and safe fluid delivery and uninterrupted vital signs monitoring for critically ill patients and sedated children during MRI scans[23](index=23&type=chunk)[25](index=25&type=chunk) [Conference Call Information](index=3&type=section&id=Conference%20Call) The company held a conference call on May 5, 2025, to discuss its Q1 2025 financial results, with a webcast and recording available on its investor relations website - A conference call to discuss the earnings release was scheduled for **9:00 a.m. Eastern Time** on **May 5, 2025**[20](index=20&type=chunk) - The call was made available via webcast on the company's investor relations website, with a recording available after the event[21](index=21&type=chunk)

Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2025. The Company is a leader in developing innovative magnetic resonance imaging ("MRI") compatible medical devices. The Company is a provider of (i) non-magnetic intravenous ("IV") infusion pump system and (ii) a ...

Company Overview - IRADIMED CORPORATION is a leader in developing innovative MRI-compatible medical devices, specifically known for its non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3]. - The company has developed the MRidium® MRI compatible IV infusion pump system, which features a non-magnetic ultrasonic motor and non-ferrous parts to ensure safe and predictable delivery of anesthesia and IV fluids during MRI scans [3]. Product Offerings - The 3880 MRI compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to operate in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4]. - The Iradimed 3880 system includes features such as wireless ECG, wireless SpO2, non-magnetic respiratory CO2 monitoring, and advanced multi-gas anesthetic agent unit, facilitating effective communication of vital signs to clinicians [4]. Upcoming Events - The company will release its 2025 first quarter financial results before the market opens on May 5, 2025, followed by a conference call at 9:00 a.m. Eastern Time to discuss the results [1]. - Interested participants can register for the conference call through a provided link, and a recording will be available on the company's website after the call [2].

Core Viewpoint - Iradimed Corporation will release its 2025 first quarter financial results on May 5, 2025, and will host a conference call to discuss these results [1] Company Overview - Iradimed Corporation is a leader in developing MRI-compatible medical devices, specifically known for its non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3] - The company has developed the MRidium® MRI compatible IV infusion pump system, which eliminates dangers associated with standard infusion pumps that contain magnetic components [3] - The Iradimed 3880 MRI compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to operate in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4] Product Features - The MRidium® system provides accurate and safe delivery of anesthesia and IV fluids during MRI scans, crucial for critically ill patients and children who require sedation [3] - The Iradimed 3880 system features wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2 monitoring, and advanced multi-gas anesthetic agent unit capabilities [4]